Subgroup analysis by fitness criteria of patients (pts) with blastic plasmacytoid dendritic cell neoplasm (BPDCN) treated with first-line (1L) tagraxofusp (TAG).

Authors: Naveen Pemmaraju, Marco Herling, Kendra Lynn Sweet, Anthony Selwyn Stein, Sumithira Vasu, Todd Louis Rosenblat, David Rizzieri, Cristina Papayannidis, Eunice S. Wang, Marina Konopleva, Michael Zuurman, Alessandra Tosolini, Muzaffar H. Qazilbash, Andrew A. Lane

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.6531

Source: Full article

---

Abstract

6531